Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROBES: Micronized Progesterone vs NETA in Menopausal Hormone Therapy
NCT05586724Phase 3Recruiting
- Start
- Mar 2022
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of progesterone in menopause (2 arms). Primary endpoints: Mammographic breast density at 12 months and Incidence of endometrial pathology (hyperplasia or cancer) at 12 months. Started Mar 2022; status: recruiting.
02
Drugs
progesterone
03
Conditions
menopause
Beyond the preview
Go deeper on NCT05586724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05586724.